Studies evaluating outcomes in PMBCL by EOT PET scan using Deauville criteria
| Study . | Treatment . | Frequency EOT PET-neg/PET-pos % . | PET-neg D1-3 PFS, % (y) . | PET-pos D4-D5 PFS, % (y) . | Frequency PET pos D4, % . | PET-pos D4 PFS, % (y) . | Frequency PET-pos D5, % . | PET-pos D5 PFS, %(y) . |
|---|---|---|---|---|---|---|---|---|
| Martelli et al, 201468 * | R-MACOPB | 70/30 | 99 (5) | 68 (5) | 21 | NR | 9 | NR |
| Vassilakopoulos et al, 2016 69 † | R-CHOP | 71/29 | 96 (3) | 61 (3) | 15 | 65 (3) | 14 | 57 (3) |
| Giulino-Roth et al, 201714 ‡ | DA-EPOCHR | 75/25 | 95 (3) | 55 (3) | 15 | ∼78 (3) | 11 | ∼30 (3) |
| Melani et al, 201872 § | DA-EPOCHR | 69/31 | 96 (8) | 71 (8) | 21 | NR | 10 | 50 (8) |
| Pinnix et al, 201871 ǁ | DA-EPOCHR | 62/38 | 100 (2) | 51 (2) | NR | NR | 14 | 22 (2) |
| Hayden et al, 202013 ¶ | R-CHOP | 71/29 | 92 (5) | 68 (5) | 17 | 87 (5) | 12 | 33 (5) |
| Vassilakopoulos et al, 202170 # | R-CHOP | 73/27 | 92-97 (5) | NR | 16 | 82 (5) | 11 | 44 (5) |
| Study . | Treatment . | Frequency EOT PET-neg/PET-pos % . | PET-neg D1-3 PFS, % (y) . | PET-pos D4-D5 PFS, % (y) . | Frequency PET pos D4, % . | PET-pos D4 PFS, % (y) . | Frequency PET-pos D5, % . | PET-pos D5 PFS, %(y) . |
|---|---|---|---|---|---|---|---|---|
| Martelli et al, 201468 * | R-MACOPB | 70/30 | 99 (5) | 68 (5) | 21 | NR | 9 | NR |
| Vassilakopoulos et al, 2016 69 † | R-CHOP | 71/29 | 96 (3) | 61 (3) | 15 | 65 (3) | 14 | 57 (3) |
| Giulino-Roth et al, 201714 ‡ | DA-EPOCHR | 75/25 | 95 (3) | 55 (3) | 15 | ∼78 (3) | 11 | ∼30 (3) |
| Melani et al, 201872 § | DA-EPOCHR | 69/31 | 96 (8) | 71 (8) | 21 | NR | 10 | 50 (8) |
| Pinnix et al, 201871 ǁ | DA-EPOCHR | 62/38 | 100 (2) | 51 (2) | NR | NR | 14 | 22 (2) |
| Hayden et al, 202013 ¶ | R-CHOP | 71/29 | 92 (5) | 68 (5) | 17 | 87 (5) | 12 | 33 (5) |
| Vassilakopoulos et al, 202170 # | R-CHOP | 73/27 | 92-97 (5) | NR | 16 | 82 (5) | 11 | 44 (5) |
Estimates (∼) are rounded. Frequencies of D4 and D5 reflect proportions in the entire cohort.
EOT, end of treatment; NR, not reported; neg, negative; PD, progressive disease; PFS progression free survival; pos, positive.
EOT PET scan for central review was performed on 115 patients (4 with early PD excluded); RT in 94% of PET-neg; PFS estimates NR separately in D4 and D5; however, in categories D4, 5 of 24 (21%), and in D5, and 6 of 10 (60%) patients relapsed/progressed.
Included only responding patients with PMBCL; RT in 49%; 12% received R-CHOP14; FFP reported.
Excluded 2 patients with early PD before EOT PET scan.
Survival estimates not reported separately for D4; however, 1 of 17 relapsed/progressed patient (6%) had EFS.
Included only patients with pre-PET and EOT PET scans.
Excluded 1 patient with early PD before EOT PET; RT in 11% (due to reassignment of earlier scans according to Deauville criteria; 2 patients had DA-EP OCHR; TTP reported).
Extended results of prior study: 231 responding patients; PET-neg, RT in 72%, RT (D1-2 47% vs D3 96%; 5-year FFP 100% vs 92%; mediastinal only 100% vs 96%. P = .16); PET-pos RT in 89% (D4 97% vs D5 80%); FFP reported.